In Vitro Antibody Production

BBI Solutions - the Antibody experts

Let our knowledgeable team of antibody experts fulfil your  manufacturing needs in our ISO certified, cGMP facility.  Whether you require 100mg of antibody for research purposes or 3 grams for your in vitro diagnostic assay, we have a flexible service to meet your needs. 

In vitro antibody manufacture 

We offer in vitro cell culture manufacture of monoclonal antibody in roller bottle and hollow fibre systems. Our ISO certified, cGMP* facility can accommodate the single-batch manufacture of tens of milligrams up to 5-gram quantities of antibody.  

10 mg to 1 gram In vitro monoclonal antibody manufacture via roller bottle  

Media formulations containing low bIgG fetal bovine serum, serum-free media, or animal component-free media can be used for productions when more stringent requirements are necessary. Productions are designed to limit the introduction of endotoxin. 

  • All incoming cell lines require BBI mycoplasma testing 
  • Cultures are grown in custom media and harvested for optimal antibody yield 
  • R&D and bulk production volumes are available 
  • cGMP production report is provided 
  • Monoclonal antibody containing supernatant is typically concentrated and purified prior to shipment 

We also offer custom cell culture production of other mammalian cell lines (CHO, HEK 293) in addition to our standard hybridoma service offerings. 

BBI offers scalable production models to fit your needs 

In vitro antibody production in hollow fibre  

For customers who require larger than 1 gram lot sizes and predictable yields, BBI now offers cGMP* in vitro antibody productions in a hollow fibre continuous perfusion system, significantly improving scalability and security in bulk.  

Why hollow fibre production with BBI? 

+ Batch sizes up to 5 grams 
+ Serum and animal component-free culture system • No contaminating mouse or bovine IgG 
+ Predictable long-term costs and ability for guaranteed yields 
+ Extensive expertise and capabilities in the maintenance of hybridoma cell lines, including routine subcloning 
+ Protein A purification for highly pure monomeric antibody 
+ Option to conjugate bulk productions to BBI’s gold nanoparticles, or seamlessly integrate with our lateral flow services 

There are 3 production models to fit your requirements: 

Pilot Evaluation: 

+ Evaluate productivity of cell line in hollow fibre via 4-week production run 
+ 200-400mgs of cGMP* antibody 
+ Post pilot, cell lines are eligible for fixed cost model 

Fixed Cost Model: 

+ Generate defined mass of purified monoclonal antibody 
+ Defined monoclonal antibody quantity delivered at a fixed per/mg price 

Run Time Model: 

+ If defined yield or fixed pricing is not required, run a production for a defined number of weeks in a time billing model 
+ All purified antibody generated in the time scale is delivered at the close of production run 

Ask us a Question: 

Please contact our Customer Services Team directly to discuss your requirements on tel:+44 (0) 1495 363000 or alternatively you can submit an enquiry here.

*21 CFR Part 820, For research and In Vitro diagnostic use only 

Technical Documents

There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.
There are currently no documents in this category.

Request a callback

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox